<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03604575</url>
  </required_header>
  <id_info>
    <org_study_id>LISPRO-CL</org_study_id>
    <nct_id>NCT03604575</nct_id>
  </id_info>
  <brief_title>A Study to Compare Pharmacokinetics and Pharmacodynamics of Insulin Lispro to Humalog® in Healthy Subjects</brief_title>
  <official_title>A Randomized Duble Blinded Two-way Crossover Single-dose Pharmacokinetics and Pharmacodynamics Study of Insulin Lispro (LLC &quot;GEROPHARM&quot;, Russia) Versus Humalog® (Eli Lilly) in Healthy Subjects Using the Euglycemic Clamp Technique</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Geropharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Geropharm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pharmacokinetics and pharmacodynamics study Study of 2 formulation of insulin lispro (Insulin&#xD;
      Lispro GEROPHARM vers. Humalog® Eli Lilly)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized duble blinded two-way crossover single-dose pharmacokinetics and&#xD;
      pharmacodynamics study of Insulin Lispro (LLC &quot;GEROPHARM&quot;, Russia) versus Humalog® (Eli&#xD;
      Lilly) in normal healthy subjects using the euglycemic clamp technique&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 22, 2016</start_date>
  <completion_date type="Actual">December 26, 2016</completion_date>
  <primary_completion_date type="Actual">December 26, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>two-way crossover</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>This study was blinded for Sponsor, investigators and analytical laboratory</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>-60, -30 and 0 hours (pre-dose), as well as at, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 210, 240, 270, 300, 360, 420 and 480 minutes post-dose</time_frame>
    <description>Pharmacokinetics of insulin lispro by Assessment of Observed Maximum Plasma Concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-t)</measure>
    <time_frame>-60, -30 and 0 hours (pre-dose), as well as at, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 210, 240, 270, 300, 360, 420 and 480 minutes post-dose</time_frame>
    <description>Pharmacokinetics of insulin Lispro by Assessment of Area Under the Curve From Time Zero Extrapolated to &quot;t&quot; (AUC(0-t))</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GIRmax</measure>
    <time_frame>0 hours (pre-dose), as well as at, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 210, 240, 270, 300, 360, 420 and 480 minutes post-dose</time_frame>
    <description>Pharmacodynamic of insulin lispro by Maximum Glucose Infusion Rate (GIRmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCGIR0-t</measure>
    <time_frame>0 hours (pre-dose), as well as at, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 210, 240, 270, 300, 360, 420 and 480 minutes post-dose</time_frame>
    <description>Pharmacodynamic of insulin Lispro by Assessment of GIR Area Under the Curve From Time Zero Extrapolated to &quot;t&quot; (AUC(0-t))</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Clamp Study</condition>
  <arm_group>
    <arm_group_label>Insulin Lispro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous administration of Insulin Lispro in dose 0.3 IU / kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Humalog®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single subcutaneous administration of Humalog® in dose 0.3 IU / kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Lispro</intervention_name>
    <arm_group_label>Insulin Lispro</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Humalog®</intervention_name>
    <arm_group_label>Humalog®</arm_group_label>
    <other_name>insulin lispro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent.&#xD;
&#xD;
          2. Caucasian males having a confirmed healthy diagnosis as per data of standard clinical,&#xD;
             laboratory, and instrumental examination methods.&#xD;
&#xD;
          3. Age of 18-50 (both incl.).&#xD;
&#xD;
          4. Body mass index equal to 18.5-27.0 kg/m2.&#xD;
&#xD;
          5. Volunteers' consent to all restrictions imposed during the study, including adequate&#xD;
             methods of contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute inflammatory diseases within 3 weeks before the screening period&#xD;
&#xD;
          2. Episodes of hypoglycemia in the anamnesis, or the presence in the family history of&#xD;
             cases of a verified diagnosis of diabetes mellitus in the immediate family&#xD;
&#xD;
          3. Fasting plasma glucose&gt; 6.1 mmol / L&#xD;
&#xD;
          4. HbA1C&gt; 6%&#xD;
&#xD;
          5. Oral glucose tolerance test - blood glucose level ≥ 7.8 mmol / l (2 hours after&#xD;
             loading with glucose)&#xD;
&#xD;
          6. Deep vein thrombosis of lower extremities in a history of life or in a family history.&#xD;
&#xD;
          7. Nicotine dependence (use of tobacco less than 6 months before the start of screening)&#xD;
&#xD;
          8. Taking medications, phytopreparations, biologically active supplements less than 14&#xD;
             days before screening&#xD;
&#xD;
          9. Receiving more than 10 units. alcohol per week (1 unit of alcohol is equivalent to 0.5&#xD;
             liters of beer, 200 ml of wine or 50 ml of strong alcohol) or anamnestic information&#xD;
             about alcoholism.&#xD;
&#xD;
         10. Donor blood donation in excess of 450 ml, less than 2 months before the study.&#xD;
&#xD;
         11. Participation in a clinical trial of any medications less than 3 months before the&#xD;
             start of screening&#xD;
&#xD;
         12. Positive test results for hepatitis C or hepatitis B, HIV, syphilis.&#xD;
&#xD;
         13. Anamnesis information about drug and / or drug dependence and / or substance abuse.&#xD;
&#xD;
         14. Positive test for alcohol content in the exhaled air.&#xD;
&#xD;
         15. A positive test for the content of drugs in the urine.&#xD;
&#xD;
         16. Presence of suspicions of an inflammatory disease of the urinary system as a result of&#xD;
             urinalysis.&#xD;
&#xD;
         17. Presence of mental illnesses in the anamnesis.&#xD;
&#xD;
         18. Mental, physical and other reasons that do not allow to adequately assess their&#xD;
             behavior and properly fulfill the conditions of the research protocol.&#xD;
&#xD;
         19. Any other conditions that make it difficult, according to the informed opinion of the&#xD;
             investigating physician, that volunteer participation in studies&#xD;
&#xD;
         20. Increased sensitivity in the history of heparin, insulin or any of the excipients of&#xD;
             the study drugs&#xD;
&#xD;
         21. Weighed allergic anamnesis&#xD;
&#xD;
         22. Abnormalities of the ECG and laboratory parameters from the norms&#xD;
&#xD;
         23. Deviations in basic vital signs: systolic blood pressure is below 100 mm Hg. or above&#xD;
             130 mm Hg, the diastolic blood pressure is below 70 mm Hg. or above 90 mm Hg; heart&#xD;
             rate less than 60 or greater than 80&#xD;
&#xD;
         24. Deviations in basic vital signs: systolic blood pressure &lt;100 mmHg. or&gt; 130 mm Hg,&#xD;
             diastolic blood pressure &lt;70 mm Hg. Art. or&gt; 90 mm Hg. Art. heart rate &lt;60 or&gt; 80 per&#xD;
             minute.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>In women of childbearing age, the cyclicity of the hormonal status may affect insulin sensitivity at different stages of the study. Therefore, to exclude the influence of the cyclicity factor of the menstrual period on insulin sensitivity in women, only males have been included in the this study.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>LLL &quot;BioEq&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197342</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 17, 2018</study_first_submitted>
  <study_first_submitted_qc>July 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>July 20, 2018</last_update_submitted>
  <last_update_submitted_qc>July 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Insulin Lispro</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

